Candel Therapeutics Appoints Renowned Cancer Immunology Expert to Research Advisory Board
NEEDHAM, Mass., March 18, 2025 – Candel Therapeutics, Inc. (Candel or the Company), a pioneering clinical stage biopharmaceutical company dedicated to advancing multimodal biological immunotherapies to help patients battle cancer, is thrilled to announce the addition of Elizabeth M. Jaffee, M.D., to its esteemed Research Advisory Board (RAB).
Dr. Jaffee: A Leader in Cancer Immunology and Pancreatic Cancer Research
An internationally recognized expert in cancer immunology and pancreatic cancer, Dr. Jaffee’s extensive expertise will significantly contribute to Candel’s mission. She currently serves as the Reynold R. Wiseman Professor of Cancer Research and the Deputy Director for the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine.
Impact on Candel Therapeutics
This strategic appointment bolsters Candel’s commitment to developing innovative treatments for borderline resectable pancreatic cancer. Dr. Jaffee’s knowledge and experience in this field will provide valuable insights and guidance as Candel continues to progress its clinical programs and explore new therapeutic opportunities.
- Enhanced scientific expertise: Dr. Jaffee’s deep understanding of cancer immunology and pancreatic cancer will provide invaluable insights and guidance to Candel’s team.
- Accelerated research: Her involvement will expedite the development of Candel’s multimodal biological immunotherapies for borderline resectable pancreatic cancer.
- Strengthened reputation: The appointment adds to Candel’s growing reputation as a leader in the development of innovative cancer treatments.
Impact on the World
Beyond Candel Therapeutics, Dr. Jaffee’s appointment to the RAB represents a significant step forward in the global fight against pancreatic cancer. With her expertise and Candel’s innovative approach to immunotherapies, there is potential for groundbreaking advancements in the treatment of this devastating disease.
- Hope for pancreatic cancer patients: Her involvement could lead to new and improved treatment options for the millions of people diagnosed with pancreatic cancer each year.
- Advancements in cancer research: Dr. Jaffee’s guidance and Candel’s innovative research could pave the way for new discoveries in cancer immunology and immunotherapy.
- Collaboration and innovation: The appointment fosters a collaborative environment that encourages innovation and the sharing of knowledge among leading researchers and biopharmaceutical companies.
Conclusion
Candel Therapeutics’ appointment of Dr. Elizabeth M. Jaffee, M.D., to its Research Advisory Board marks an exciting time for the company and the global fight against pancreatic cancer. Dr. Jaffee’s extensive expertise in cancer immunology and pancreatic cancer will significantly contribute to Candel’s mission, bringing hope for patients and potential advancements in cancer research. Stay tuned for updates on Candel’s progress and the impact of Dr. Jaffee’s involvement in the fight against pancreatic cancer.
